Atherosclerosis is a complex and heritable disease involving multiple cell types and the interactions of many different molecular pathways. The genetic and molecular mechanisms of atherosclerosis have, in part, been elucidated by mouse models; at least 100 different genes have been shown to influence atherosclerosis in mice. Importantly, unbiased genome-wide association studies have recently identified a number of novel loci robustly associated with atherosclerotic coronary artery disease. Here, we review the genetic data elucidated from mouse models of atherosclerosis, as well as significant associations for human coronary artery disease. Furthermore, we discuss in greater detail some of these novel human coronary artery disease loci. The combination of mouse and human genetics has the potential to identify and validate novel genes that influence atherosclerosis, some of which may be candidates for new therapeutic approaches. (Circ Res. 2012;110:337-355.)
T he process of atherosclerosis has been the topic of substantial investigation over many decades. Atherosclerosis is a complex process that has a strong heritable component and involves a number of cellular processes and molecular mechanisms. Exploiting genetic manipulation in mice and natural genetic variation in humans has the potential to inform our understanding of the pathophysiology of atherosclerosis and identify novel targets for therapeutic intervention. In this article, we first review the data involving deletion of specific genes in mice and the effect on atherosclerosis, as well as unbiased approaches to discovery of genetic loci associated with atherosclerosis in mice. Then, we review the current status of human genetic variation and its association with coronary artery disease.
Genetics of Atherosclerosis in Mice
The most widely used in vivo model for human atherosclerosis is currently the mouse. Wild-type mice fed a chow diet are not susceptible to atherosclerosis, and this has led investigators over the years to develop three primary mouse models for examining atherosclerosis. First is the cholesterol-cholate diet is a high-fat (15%), cholesterol (1.25%), and cholate (0.5% cholic acid) diet known as the Paigen diet and is primarily used to induce atherosclerosis in wild-type mice. The combination of cholesterol and cholate facilitates cholesterol and fat absorption, suppresses the conversion of cholesterol to bile acid, which reduces cholesterol clearance, resulting in increased plasma cholesterol. 1 The cholate also affects gene expression of lipid, lipoprotein, and inflammatory genes, and the net result is increased atherosclerosis in mice. 2, 3 However, lesion sizes in mice maintained solely on the Paigen diet remain small; 4 therefore, this strategy has not been as extensively used as the other two models. Second, low-density lipoprotein (LDL) receptor knockout (KO) mice (Ldlr Ϫ/Ϫ ) lack the primary receptor for LDL cholesterol uptake, causing a modest increase in plasma LDL cholesterol levels; 5 however, to induce atherogenesis, Ldlr Ϫ/Ϫ mice must have their plasma cholesterol levels increased further through the feeding of a Western-type diet (WTD) 6 or crossing with another model such as the Apobec1 knockout mouse. Third, apolipoprotein E (ApoE) KO mice (Apoe Ϫ/Ϫ ) lack the primary lipoprotein required for the uptake of lipoproteins through the hepatic receptors, leading to even greater plasma cholesterol increase than the Ldlr Ϫ/Ϫ mice, and consequently atherosclerosis can be observed in Apoe Ϫ/Ϫ mice maintained on a regular chow diet, with advanced disease observed when the mice are maintained on a WTD ( Figure 1A) . 5, 7, 8 
Candidate Gene Approaches in Mice
In a candidate gene loss-of-function approach, a KO mouse model for the specific gene is interrogated using the models outlined. If the Paigen diet is used, then no backcrossing is required; however, generally double KO mice are generated by crossing the candidate KO with either Ldlr Ϫ/Ϫ or Apoe Ϫ/Ϫ mice. Using these approaches, approximately 100 genes have been reported to robustly and significantly affect atherosclerosis in mice at a significance threshold of PϽ0.01. Of these 100 genes, approximately 60% of initial studies were performed using the Apoe Ϫ/Ϫ background, 25% were performed using the Ldlr Ϫ/Ϫ , 5% tested both backgrounds, and 10% were performed using the Paigen diet. Of the 100 genes, deletions of 65 were shown to decrease atherosclerosis, whereas deletion of 35 increased atherosclerosis. The 100 genes generally fall into two categories, those that affect atherosclerosis by influencing plasma lipids (nϭ33; Table 1 ) and those that do not substantially influence plasma lipids and therefore presumably work through other pathways (nϭ67; Table 2 ).
In a candidate gene gain-of-function approach, the generation of overexpression transgenic mice in the Apoe Ϫ/Ϫ or Ldlr Ϫ/Ϫ background has been applied. This approach has several advantages; it allows the examination of genes when knockouts are embryonic lethal and it allows for the examination of human specific genes, such as cholesteryl ester transfer protein, which does not have a mouse ortholog. 9 Additional methods for probing the role of specific genes in mouse atherosclerosis include bone marrow transplantation to show the effects on atherosclerosis from hematopoetic- expressed genes (such as with Abcg1 10 ), antibody-inhibition studies, 11 and small molecule pharmacological studies; 12 however, those studies are not reviewed here in the interest of space.
Many genes that were tested have no or minimal effect on atherosclerosis, or have not been replicated. On several occasions, genes have been reported to have an effect only under certain conditions, such as in the Icam1 Ϫ/Ϫ mouse studies in which atherosclerosis is affected on the Apoe Ϫ/Ϫ background, 13 but not in the Ldlr Ϫ/Ϫ background. 14
Unbiased Mapping Approaches in Mice
In addition to testing specific genes for their effects on atherosclerosis, mice have also been used to identify athero- sclerosis genes using unbiased mapping approaches specifically through the use of quantitative trait locus (QTL) analysis. Thus far, 43 significant mouse QTL have been mapped in mice for atherosclerosis ( Table 3 ). 15 QTL mapping typically involving an F2 generation from two progenitor strains still requires a proatherogenic model to map atherosclerosis loci. Of the 43 loci identified, 19 have been mapped using progenitor strains that had the Apoe Ϫ/Ϫ gene introduced, 12 were mapped using strains with Ldlr Ϫ/Ϫ , and an additional 12 QTL were mapped simply by maintaining the F2 mapping population on the Paigen diet. The nature of QTL analysis makes identifying causal genes extremely difficult, because the mapped loci (confidence intervals) typically include hundreds of genes with dozens of plausible candidates, even after applying advanced mapping strategies and bioinformatics. 16 -24 Consequently, plausible candidates for just a small number of atherosclerosis QTL have been successfully mapped. Artles1 was the first atherosclerosis QTL to be positionally cloned as the gene arachid- onate 5-lipoxygenase (Alox5), 25 and the atherosclerosis phenotype was confirmed in Alox5 Ϫ/Ϫ mice, 26 although other investigators did not see the same effect. 27 Historically, many KO mice have been generated with the use of embryonic stem cells derived from the "129" strain, subsequently backcrossed to the more standardized "C57BL/6 (B6)" strain. However, no matter how many backcrosses are performed to B6, a significant proportion surrounding the locus of the KO gene will continue to remain from the 129 strain because of linkage, the so-called passenger gene region. 28 These genes will contain polymorphisms between the embryonic stem donor strain and the backcrossed recipient strain, and could affect the phenotype being examined, leading to a false conclusion that the KO gene is solely responsible for the QTL effect. 28, 29 As we summarize, ALOX5 has not been convincingly proven in human genetic studies to be associated with CAD; however, CXCL12 which is significantly associated with human CAD, maps to the orthologous mouse chromosome (Chr) 6 at 117.1 million bases (Mb) from the acromere, less than 1 Mb away from Alox5 (116.3 Mb) and within the so-called passenger gene region of the Alox5 Ϫ/Ϫ strain. Consequently, polymorphisms between 129 alleles in Cxcl12 and B6 control mice may be a significant contributor to the Artles1 QTL.
A causal gene was also reported for Ath1, one of the first atherosclerosis QTL ever mapped in mice, which is located on distal mouse Chr1. 30 The gene was identified as tumor necrosis factor (ligand) superfamily member 4 (Tnfsf4, also known as Ox40l). Tnfsf4 Ϫ/Ϫ mice showed decreased atherosclerosis, and two human populations that were examined reported single nucleotide polymorphism (SNP) having marginal significance for myocardial infarction (MI) (PϽ0.05). 31 However, other investigators did not observe the significance of those SNPs to MI in their human populations 32 and, as presented later, there is currently no genome-wide association locus reported near the human ortholog TNFSF4 at the syntenic human location (Chr1 at 173Mb). A third QTL, a disintegrin and metalloproteinase 17 (ADAM17), was proposed as the causal gene for an atherosclerosis QTL on mouse Chr 12; however, the effect in Adam17 Ϫ/Ϫ has not yet been reported. 33, 34 Mice have proven extremely powerful in identifying genes and loci that affect atherosclerosis. More than 100 gene deletion mouse models have revealed detailed biological processes leading to atherosclerosis, crucial insights into the nature of specific causal mechanisms affected by lipid metabolism, inflammation, and the pathogenesis of atherosclerosis itself. It is also interesting to note that many of these genes have shown large effect sizes, typically 20% to 50%. It is therefore likely that deletion of more than one of these genes would not have an additive effect. It is possible that many of the genes act in common pathways, leading to atherosclerosis. These genes may be under large selection pressure in humans, preventing null mutations from arising in the general population, which may partly explain why few of these genes have been robustly shown to affect CAD in humans but nonetheless could be relevant to human CAD pathology.
A further point that might explain the large number of mouse atherosclerosis genes that have not been convincingly validated in humans could be the differences in pathogenesis and phenotyping of atherosclerosis between mouse and human ( Figure 1 ). The most important clinical consequences of atherosclerosis in humans arise from lesions in the coronary, carotid, and cerebral arteries, whereas the focus in mice is on the aorta and proximal great vessels. The size, structure, hydrodynamics, embryonic origin and abundance of the smooth muscle cells, and the elasticity of the arteries differ considerably between mouse and humans. 35 Furthermore, although plaque disruption and thrombosis are major causes of cardiovascular events in humans, similar events have not been convincingly demonstrated in mice. Perhaps then it is not surprising that translation of the genetic discoveries in mice to human CAD susceptibly has been slow and unconvincing; however, this has not necessarily been solely attributable to the limitations in the mouse model.
Human genetics has, until recently, been considerably underpowered to identify significant genetic associations with CAD. As human studies continue to increase in power, more of the genes and loci identified in the mouse may be replicated in humans. Nonetheless, recent human genetic susceptibility loci, as we discuss, have been identified in genes and loci that could not have been extrapolated from the accumulated knowledge of these mouse studies. This leads to the conclusion that current mouse model strategies for studying atherosclerosis, relevant to human genetics and biology, may need to be revised.
Genetics of Atherosclerosis in Humans
The relationship of genetic variation to atherosclerotic cardiovascular disease in humans has the potential to provide important information on the pathophysiology of atherosclerosis in humans. However, the ability to identify causal genes in human studies has, until recently, been limited by low sample sizes and heterogeneity in predictive subclinical phenotypes ( Figure 1B) . 36, 37 The expectation is that there would be numerous genes underlying the susceptibility to atherosclerosis in the general population, and that each would have small effects, similar to all complex traits. 38 There have been hundreds of candidate gene studies and multiple linkage studies. Although some of these studies identified "significant" genetic associations with particular genes and polymorphisms, numerous other studies failed to replicate those associations, and specific replication studies have showed that most of those loci could not be replicated. 39 More recently, genome-wide association studies (GWAS) have unearthed multiple loci significantly associated with CAD, many of which have been replicated numerous times independently and across ethnic groups. Here, we briefly review the candidate gene and human linkage studies, and then focus primarily on the new developments related to GWAS of CAD.
Candidate Gene Studies in Humans
Using the candidate gene approach, polymorphisms in specific genes with plausible biological relevance are genotyped to determine association with CAD. The candidate gene approach has revealed some loci with significant and convincing effects on atherosclerosis. 40, 41 However, overall the traditional candidate gene approach has yielded a slew of negative studies or weak associations that could not be replicated. The candidate gene approach for CAD took a more high-throughput approach several years ago with the development of the cardiovascular gene-centric 50K SNP array. 42 This array was designed specifically to examine variants in CAD candidate genes, and a recent meta-analysis involving Ͼ30 000 cases and Ͼ75 000 controls revealed several new genes highly significantly associated with CAD.
Linkage Studies
Although traditional risk factors such as age, gender, and family history are still better predictors of CAD than genetic markers and genetic scores, twin studies demonstrate a strong heritable component of genetic susceptibility to atherosclerosis. In rare instancesm atherosclerosis can appear as a Mendelian disorder, such as in familial hypercholesterolemia (FH), in which mutations in the LDL receptor significantly increase plasma LDL cholesterol and, consequently, atherosclerosis susceptibility. 43 However, even in FH, there is wide variation in atherosclerosis. Family-based linkage studies have been deployed to identify atherosclerosis loci in an unbiased approach and such linkage studies can be applied in two general ways: by examining multiple large families in a QTL type approach or by examining a single very large family using a Mendelian inheritance hypothesis. As with the mouse QTL mapping, the linkage regions using either approach are typically too large to identify plausible causal genes. 44 More than 40 loci have been identified using human linkage studies for different measures of human CAD (MI, acute coronary syndrome, coronary calcification, carotid intimal-medial thickness, and peripheral arterial occlusive disease), although few of the loci have been replicated between studies. In several instances, strong candidate genes were identified, including lipoprotein receptor-related protein 6 (LRP6) at 12q13.2, 45 arachidonate 5-lipoxygenaseactivating protein (ALOX5AP) at 13q12-13, 46 and myocyte enhancer factor 2A (MEF2A) at 15q26.3. 47 Atherosclerosis screening in mouse models has not yet been reported for these genes, and the new GWAS loci discussed later map outside of the original confidence intervals, which identified LRP6 and ALOX5AP, indicating these may be distinct loci. MEF2A is more controversial than the other two genes, 44, 48 and maps just 20Mb away from ADAMTS7 (discussed below) on chromosome 15 which may represent linkage of MEF2A to a broader region that includes ADAMTS7. Like mouse QTL analysis, family based linkage studies have been very successful in identifying loci, but have yielded a limited a number of convincing genes that affect atherosclerosis.
GWAS
Human GWAS examine millions of polymorphisms simultaneously to examine association to a phenotype in a large unrelated but ethnically similar population, and the phenotype is treated either as a continuous variable or as a case-control binary population comparison. Because there is a large number of tests performed simultaneously, the currently accepted threshold for genome-wide significance is PϽ5ϫ10 Ϫ8 . 49 For GWAS of CAD, the case-control approach has been the most commonly reported, and this has yielded multiple loci with highly significant associations with MI and CAD (Table  4 ). In 2007, this approach successfully identified a locus at chromosome 9p21.3 that was highly associated with risk of MI and CAD. 50 -52 Concurrently, the Wellcome Trust Case Control Consortium 53 reported seven additional novel genome-wide significant loci for MI. Further studies and metaanalyses have added additional significant loci. 50,54 -58 The most recent and extensive findings come from two global consortia, CARDIoGRAM 59 and C4D, 60 and bring the total number of genome-wide significant loci for MI/CAD to 34 ( Table 4 ). The CARDIoGRAM consortium pooled the data from 14 different GWAS for a total of 140 000 patients and reported 13 new loci that are genome-wide significant for CAD, whereas the C4D consortium examined 70 000 patients focusing on South Asians and Europeans and identified four further loci. Beyond the 34 current loci, there are many hundreds of other SNPs that are nominally significant (5ϫ10 Ϫ8 ϾPϽ0.05). These may harbor important genes that will reach significance in larger meta-analyses, and further information gained from expression QTL and bioinformatics 16 may provide reason to investigate some of these nominally significant loci more urgently. Information from many of the genes derived from mouse atherosclerosis studies that have nominally significant human associations with CAD may also provide impetus to investigate those genes further.
Several of the CAD loci are significantly associated with LDL cholesterol levels (Table 4) , whereas three-quarters of all the CAD loci were completely novel and were not previously suspected to be involved in atherosclerosis or MI. The majority of the loci have not even been shown to be significantly associated with other CAD risk factors such as diabetes mellitus, hypertension, or body mass index (BMI). Conversely, many lipid genes, inflammatory genes, and genes previously shown to affect other CAD risk factors have not yet been validated by unbiased human GWAS studies, at least by the high bar of being genome-wide significant. 42 Notably, several novel CAD loci are associated with lipids (SORT1, TRIB1, and LPA) and others are related to blood pressure and hypertension, 61 suggesting that these risk factors lie in the causal pathway for these particular genes. However, it appears highly likely that the majority of CAD loci will remain unassociated with known risk factors. Furthermore, little is known about the biology of most of the genes at these loci and the mechanisms by which they may influence atherosclerosis or MI.
Examples of Novel CAD Loci Identified by GWAS and Implications for Pathophysiology of Atherosclerosis 9p21(CDKN2A-B/ANRIL/MTAP)
The 9p21 locus was the first CAD locus discovered using GWAS and has been reliably reproduced, remaining the strongest association with CAD in the human genome. 54 This locus has long been known to be involved in cancer susceptibility; 62 however, there are no associations with known risk factors of CAD such as hyperlipidemia or hypertension. 56 The
SNPs associated with CAD are all located in intergenic locations, rather than in coding or gene regulatory regions such as untranslated regions (UTRs) or promoter regions (Figure 2A ). Consequently, identifying and characterizing the causal variant and gene have been challenging. None-theless, several studies have begun to characterize the functional aspects of this locus, focusing on the nearest genes: cyclin-dependent kinase inhibitor 2A (CDKN2A), the homologue CDKN2B, 63, 64 and the neighboring noncoding transcripts. BP, blood pressure; CAD, coronary artery disease; CKD, chronic kidney disease; Mb, million bases. *SNP associations made in the IBC 50K SNP array in which a lower threshold is required for genome-wide significance because of fewer tests being performed (PϽ1ϫ10 Ϫ6 ). Mb indicates the location of the reported SNP in millions of bases from the proximal end of the chromosome, assembly NCBIM37 2011.
SNP indicates the most commonly reported SNP for the locus; however, there may be multiple genome-wide significant SNPs in the locus in independent linkage disequilibrium spanning thousands of bases.
Band indicates chromosome, arm, and chromatin band of the locus.
Related associations indicate that the locus, typically the same SNP listed in the Table, has been reported as genome-wide significant for a phenotype known to affect CAD.
The two primary genes CDKN2A and CDKN2B are present on the same strand and encode several different splice variants; CDKN2B encodes the p15 protein, whereas CDKN2A encodes the p16 protein as well as the p14/ARF protein (p19/ARK in mice), although because of alternative splicing p16 and p14 share no homology at the amino acid level. 65 More recently, an additional antisense (relative to CDKN2B) noncoding RNA was identified and termed ANRIL. The first exon of ANRIL is in the promoter of p14 (CDKN2A) and overlaps with two exons of p15 (CDKN2B), and is now referred to as CDKN2B-antisense (CDKN2B-AS). 66 Because of the increased attention at this locus, additional noncoding antisense transcripts on the "ϩ strand" have been identified that overlap with these sequences. Furthermore, the gene coding for methylthioadenosine phosphorylase (MTAP) has been shown to have multiple alternative transcripts, both coding and noncoding. Two of the noncoding MTAP transcripts have shared exons with ANRIL. Finally, there is also a new small protein-coding gene called C9ORF53, which encodes a 79 amino acid protein and remains largely uncharacterized.
Although it is still unclear which of the genes at this locus is specifically responsible for the CAD association and what the mechanism may be, functional studies have implicated enhancer activity for the neighboring genes. 63, 64 One study examining mRNA expression of the genes at the locus from peripheral blood mononuclear cells, with follow-up in a much smaller sample size of atherosclerosis plaque tissue, suggested that transcript levels of ANRIL (CDKN2B-AS), but not CDKN2A, 2B, C9ORF53, and MTAP, are associated with atherosclerosis. 67 However, CDKN2B-AS/ANRIL has not yet been identified in mice, which will make in vivo character-ization of such an effect difficult. Mice and humans differ significantly at this region for two reasons. First, there are significantly more transcripts identified for all the genes in the region in humans compared to mice. Second, much of the region that is significantly associated with CAD in humans either is missing or is not yet convincingly sequenced in mice ( Figure 2B ).
Despite this, a mouse strain with a targeted deletion of 70kb in the orthologous region on mouse Chr 4, where CDKN2B-AS/ANRIL should be (Chr4 ⌬70kb/⌬70kb ), significantly affects cardiac expression of the neighboring genes and the proliferation properties of vascular cells. Cardiac expression of Cdkn2a and Cdkn2b is reduced in Chr4 ⌬70kb/ ⌬70kb mice, indicating that the locus may be a long range regulator for genes that affect CAD through cardiac and vascular cell proliferation, possibly via CDKN2A and CDKN2B. 64 Studies using human cells of defined genotype showed that lymphoblastoid cells homozygous for the "protective " haplotype showed binding of STAT1 to an enhancer in this region, whereas cells homozygous for the "risk" haplotype had no STAT1 binding. Interferon-␥ stimulation and STAT1 binding was shown to regulate CDKN2B and CDKN2B-AS expression in human vascular endothelial cells. Thus, genetic variation within enhancers at the 9p21 locus may influence vascular cells responses to inflammatory stimuli, resulting in effects on atherogenesis. 68
ADAMTS7
The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family of proteases comprises 19 discrete proteins that are zinc metalloproteases. These proteins are secreted and interact with, and degrade components indicates that there is a region lacking overlapping sequenced contigs (designated "unknown sequence"), which may be as large as 50 000 bases. The sequenced contigs flanking this region are small and may indicate a region of excessive repetitive DNA preventing the ability to confidently sequence the region.
of, the extracellular matrix. Some ADAMTS family members have partially defined biological functions. ADAMTS13 is the protease that cleaves von Willebrand factor, and mutations in ADAMTS13 cause thrombotic thrombocytopenic purpura. ADAMTS2, ADAMTS3, and ADAMTS14 regulate the maturation of procollagen into mature collagen via cleavage of an N-terminal preprotein region, and thus these proteins are collectively known as the procollagen-nproteinases. 69 Finally, many other ADAMTS proteins are known to bind and cleave numerous proteoglycans such as aggrecan, versican, and brevican. 70 There are multiple lines of evidence linking the ADAMTS family of metalloproteases with the pathogenesis of atherosclerosis. The observation that multiple ADAMTS (ADAMTS1, ADAMTS4, and ADAMTS9) proteins can cleave versican, a proteoglycan both highly expressed in regions of the vasculature prone to plaque formation 71 and associated with adult cardiovascular disease, 72 suggests a role for these proteins in plaque formation. Multiple ADAMTS proteins are expressed in human carotid lesions. 73 Specifically, ADAMTS1 localizes with vascular smooth muscle cells (VSMCs) within lesions and its expression is higher in migrating and proliferating VSMCs. 74 ADAMTS4 localizes with macrophages in atherosclerotic lesions and demonstrates higher levels of expression during plaque development in atherosclerotic mouse models. 73 Additionally, SNP in ADAMTS1 has been associated with a nearly two-fold increase in cardiovascular disease. 75 In a recent GWAS meta-analysis involving patients with (nϭ12 393) and without (nϭ7383) CAD, as ascertained by coronary angiographic phenotyping, the SNP most highly associated with CAD lies in an intron of the ADAMTS7 gene (Pϭ5.0ϫ10 Ϫ13 ). 76 This finding was replicated by the CARDIoGRAM consortium. 55 The linkage disequilibrium block that this SNP lies in is completely encompassed by the ADAMTS7 coding region, strongly implicating ADAMTS7 as the causal gene. ADAMTS7 can bind and cleave the cartilage oligomeric matrix protein (COMP), an interaction thought to play a role in the progression of arthritis. 77 More recently, ADAMTS7 overexpression was shown to increase neointimal formation postinjury in a rat carotid artery balloon injury model. 78 Subsequent knock-down of ADAMTS7 expression by topical application of siRNAs decreased postinjury neointimal formation. Overexpression and underexpression of ADAMTS7 also increased and decreased primary VSMC migration, respectively, 78 whereas exogenous expression of COMP decreased both postinjury neointimal formation as well as primary VSMC migration. The statistical analyses in human cohorts combined with in vivo model observations suggest that ADAMTS7 is likely to play a causal role in atherogenesis, presumably through enhanced VSMC infiltration and migration in plaques. These results also make ADAMTS7 an exciting target for future studies and potential therapeutic intervention.
CXCL12
Most of the CAD GWAS loci do not harbor classical inflammatory genes (Table 4 ). One exception is the 10q11 locus near the gene CXCL12, previously known as stromal cell-derived factor 1 (SDF-1). The most significant SNPs at this locus are in fact in a gene desert located between two noncoding uncharacterized transcripts, with CXCL12 being the nearest gene located approximately 100 000 bases away. CXCL12 is a complex gene with two common splice variants (␣ and ␤), and up to six additional coding variants. CXCL12 is known to have a major role in angiogenesis and is a key regulator of endothelial cell responses, as well as having anti-inflammatory properties by modulating the accumulation of leukocytes and bone marrow-derived stem cells in inflamed tissue. 79 Additional evidence that CXCL12 is the causal gene for atherosclerosis at this locus was recently reported in a clinical study examining two CAD populations. The risk allele for the SNP (rs1746048) was shown to be associated with increased atherosclerosis and higher CXCL12 mRNA transcript levels, particularly for the ␣-isoform in human liver and natural killer cells. 80 In addition, the risk allele was reported to confer increased plasma protein levels of CXCL12, 80 indicating that higher plasma CXCL12 might result in increased atherosclerosis. However, in a smaller human study, CXCL12 levels were lower in subjects with unstable angina. 81 Additionally, KO mouse data (Cxcl12 Ϫ/Ϫ ) indicate that deficiency of CXCL12 is likely to be detrimental to health because it is required for B-cell lymphopoiesis, myelopoiesis, correct formation of the ventricular septum, 82, 83 and T-cell development. 84 The Cxcl12-␣ variant in mice has also been shown to confer protection against myocardial ischemia/reperfusion injury. 85 Additional studies to overexpress Cxcl12 in mice would be a useful in clarifying the biological effects of increased CXCL12, but it is possible that differential tissue specific roles may be involved, that the mouse response may differ from human, and that acute vascular injury models may differ from chronic atherosclerosis models.
ABO Blood Group, Transferase A, Alpha 1-3-N-Acetylgalactosaminyltransferase, Transferase B, Alpha 1-3-Galactosyltransferase
The ABO blood groups were associated with plasma cholesterol levels by the Framingham Study Ͼ35 years ago. 86 The same study linked ABO blood groups with intermittent claudication, 86 and various other studies at that time also drew links to ischemic heart disease, 87,88 atherosclerosis obliterans, 87, 89 and venous thromboembolism. 87, 88 Despite these early significant discoveries, the mechanism regarding how different ABO groups affect lipids and cardiovascular disease remain unknown. GWAS studies have recently "rediscoverd" the ABO locus to be both genome-wide significant for LDL cholesterol, 90 as well as with MI, whereby the O blood group affords protections from MI in patients with angiographic CAD. 76 The specific mechanisms by which the ABO gene locus influences multiple cardiovascular risk factors and MI remain unclear. One reason for the lack of progress is that studying glycoconjugates is considerably more difficult than simply studying nucleic acids or proteins, 91 and because there is a distinct lack of an appropriate in vivo animal, and specifically mouse, models for the human ABO locus. 92
Conclusions
Our review of the mouse model literature reveals a large list of genes that have been shown to affect atherosclerosis in mice. However, few of these have shown up in human genetic studies to be genome-wide significantly associated with CAD, although some of these mouse atherosclerosis genes may become significant with larger human genetic studies. The gene-centric cardiovascular genotyping array (IBC 50K CAD Consortium) was designed to include many CAD candidate genes that arose from mouse studies, and this approach has been successful in adding several unique associations to the current list of 34 genome-wide significant loci. 42 Targeting more of the genes identified from mouse studies through gene-centric approaches and resequencing could identify more genes that affect human CAD. Nonetheless, currently there remains substantial "missing genetic heritability" for human CAD. 93 Mouse QTL for atherosclerosis may have some overlap with the recent human GWAS loci; however, most of these QTL remain large and even with novel bioinformatic approaches identifying candidate genes from these QTL remains difficult. Denser genotyping in mouse crosses provides little extra power because of the relatedness of the strains and the limited recombination events. The future Collaborative Cross, which is generating hundreds of densely genotyped recombinant-inbred strains, may help generate more finite QTL intervals, although this may prove difficult for atherosclerosis given that if the new strains are not prone to atherosclerosis each will have to be crossed to Apoe Ϫ/Ϫ or Ldlr Ϫ/Ϫ strains. 94 -96 It is also possible that some of the associations of these genes with murine atherosclerosis are false-positives, arising because of variants in nearby causal "passenger genes" or to biology, which is specific to the common mouse atherosclerosis models, predominantly Apoe Ϫ/Ϫ and Ldlr Ϫ/Ϫ background mice. The limitations of mouse models may be much more substantial and pernicious than previously recognized. It is apparent from recent human GWAS that there is almost no overlap with the rodent KO models, and that the rodent QTL have not been sufficiently specific to demonstrate overlap, even after at least 34 genome-wide significant loci for human CAD have been described. It is therefore important to illustrate the potential limitations of the commonly used mouse CAD models so that they can be avoided or minimized in future functional studies. The key issues include: (1) current models utilize extreme hypercholesterolemia to induce atherosclerosis-this may be a particularly nonphysiological model for the study of nonlipid candidate genes that appear to be more abundant than lipid genes based on recent human GWAS and (2) there is a lack of homology between mouse and human for key genes of interest; for example, cholesteryl ester transfer protein is not expressed in mouse, the 9p21 locus is markedly different between human and mouse, and the ABO variants are substantially different between mouse and human.
Moving forward we can expect a more human-translational strategy with mouse studies focused on validating the recent human loci and genes. This will require reasonable genetic homology between mouse and human but, more importantly, there must be a renewed effort to apply new and improved mouse models, particularly with less extreme lipid disturbance for loci with no impact on lipids themselves.
The human heritability of CAD is estimated to be between 30% and 60%. 97 The recent large-scale meta-analysis of human GWAS data reveals 34 significant loci, and the accumulation of these loci explains just 10% of the heritability of CAD. 98 Many reasons have been provided as to why the detected human genetic variance for complex traits is so low; GWA studies only examine SNPs and neglect much of the other forms of genomic variation, such as deletions, insertions, inversions, duplications, copy number variants, as well as imprinting/epigenetics, epistasis (gene-by-gene and geneby-environment), and that there is lack of statistical power to assess rare variants. 93 However, even though only 10% of human CAD variation is currently explained, it is explained by mostly novel loci that have not yet been investigated. Each of these loci may contain therapeutically targetable genes that may go a long way to reduce CAD incidence, and certainly there remains a lot of work to be performed to uncover the functional biology of these novel genes and the mechanisms by which they are related to atherosclerosis.
In terms of human studies, traditional risk factors such as age, sex, smoking, and a family history of premature coronary heart disease are still more predictive of CAD than human genetic markers and genetic scores. Aging in particular affects all metabolic processes and has a profound effect on atherosclerosis, and we do not yet fully understand the impact of aging at the cellular level. However, it is intriguing that some of the new GWAS loci contain genes involved in immunity and cell growth because aging is known to affect these crucial mechanisms. Future more detailed stratified meta-analyses and assessment of interaction effects may yield important gene-by-environment interactions and help aid in deciphering the causal mechanism.
Overall, mouse models of atherosclerosis, particularly the candidate gene-based approaches, have helped us discover and understand many intricacies of the disease and have provided some insight, albeit biased, into the biology of the disease. Recent human GWAS have elucidated a substantial number of novel loci and genes, indicating that we still have some way to go before we fully understand the genetic mechanisms and biological pathways causally involved in human atherosclerosis.
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